Business Wire

Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis

-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the ...
Nasdaq

Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis

- Phase 2 data demonstrated that a once-daily triple combination of VX-121/ tezacaftor/VX-561 has potential for enhanced clinical benefit compared to TRIKAFTA ...
AOL

Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for t

Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation -Global ...
FierceBiotech

Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of a global pivotal Phase 3 development program for fixed-dose combinations of ...
Nasdaq

Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed

Vertex Pharmaceuticals IncorporatedVRTX announced that two phase III studies evaluating its next-generation CFTR corrector, VX-445 in combination with tezacaftor and Kalydeco (ivacaftor) met the ...